SEC Form 4 · accession 0001209191-17-054440
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Nagler
Officer — SVP, HR & Corp. Affairs
Period of report
Sep 27, 2017
Accepted (ET)
Sep 29, 2017 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 27, 2017 | M | 3,750 | $2.1852 | A | 3,750 | D | |
| Common Stock | Sep 27, 2017 | S | 3,750 | $30.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.1852 | Sep 27, 2017 | M | 3,750 | D | — | Feb 4, 2025 | Common Stock | 3,750 | 37,347 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.